Log in

NASDAQ:BLFSBioLife Solutions Stock Price, Forecast & News

$16.45
-0.17 (-1.02 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.72
Now: $16.45
$16.69
50-Day Range
$9.53
MA: $13.09
$16.62
52-Week Range
$7.37
Now: $16.45
$21.18
Volume170,600 shs
Average Volume208,723 shs
Market Capitalization$336.40 million
P/E Ratio40.12
Dividend YieldN/A
Beta1.53
BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Read More
BioLife Solutions logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.62 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLFS
CUSIPN/A
Phone425-402-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.37 million
Cash Flow$0.20 per share
Book Value$2.12 per share

Profitability

Net Income$-1,660,000.00

Miscellaneous

Employees54
Market Cap$336.40 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.

BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

How has BioLife Solutions' stock been impacted by COVID-19 (Coronavirus)?

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLFS stock has increased by 34.3% and is now trading at $16.45. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioLife Solutions?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioLife Solutions.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioLife Solutions.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions Inc (NASDAQ:BLFS) released its quarterly earnings results on Wednesday, March, 11th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.04. The medical equipment provider had revenue of $8.30 million for the quarter, compared to analyst estimates of $8.72 million. BioLife Solutions had a return on equity of 4.80% and a net margin of 97.57%. View BioLife Solutions' earnings history.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its first quarter 2020 IntraDay earnings guidance on Friday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $12.1-12.1 million, compared to the consensus revenue estimate of $9.72 million.

What price target have analysts set for BLFS?

8 analysts have issued 1-year price targets for BioLife Solutions' stock. Their forecasts range from $17.00 to $25.00. On average, they expect BioLife Solutions' share price to reach $21.75 in the next year. This suggests a possible upside of 32.2% from the stock's current price. View analysts' price targets for BioLife Solutions.

Has BioLife Solutions been receiving favorable news coverage?

News articles about BLFS stock have trended very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioLife Solutions earned a news sentiment score of 3.5 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutBioLife Solutions.

Who are some of BioLife Solutions' key competitors?

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Square (SQ), Amarin (AMRN), Cara Therapeutics (CARA), Crispr Therapeutics (CRSP) and Walt Disney (DIS).

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:
  • Mr. Michael P. Rice, Pres, CEO & Director (Age 56)
  • Mr. Roderick de Greef, CFO & Sec. (Age 59)
  • Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 47)
  • Ms. Karen Foster, VP of Operations (Age 59)
  • Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sentinel Pension Advisors Inc. (5.38%), Park West Asset Management LLC (4.79%), BlackRock Inc. (2.91%), Tarsadia Capital LLC (2.33%), Russell Investments Group Ltd. (2.05%) and Sandler Capital Management (2.04%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View institutional ownership trends for BioLife Solutions.

Which institutional investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including Sandler Capital Management, Russell Investments Group Ltd., Essex Investment Management Co. LLC, State Street Corp, THB Asset Management, Perkins Capital Management Inc., Morgan Stanley, and Granahan Investment Management Inc. MA. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Andrew G Hinson, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Michael Rice, Raymond W Cohen, and Todd Berard. View insider buying and selling activity for BioLife Solutions.

Which institutional investors are buying BioLife Solutions stock?

BLFS stock was purchased by a variety of institutional investors in the last quarter, including Sentinel Pension Advisors Inc., Tarsadia Capital LLC, Penn Capital Management Co. Inc., Wellington Management Group LLP, Park West Asset Management LLC, Roubaix Capital LLC, Ranger Investment Management L.P., and Squarepoint Ops LLC. View insider buying and selling activity for BioLife Solutions.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $16.45.

How big of a company is BioLife Solutions?

BioLife Solutions has a market capitalization of $336.40 million and generates $27.37 million in revenue each year. The medical equipment provider earns $-1,660,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is www.biolifesolutions.com.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.